Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane ...

Orphan status in the U.S. can confer clinical-trial tax credits, user-fee exemptions, and up to seven years of post-approval ...

NASHVILLE, Tenn. and CAMBRIDGE, England, May 13, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new ...

Add Yahoo as a preferred source to see more of our stories on Google. A 3D illustration of human lungs. The Food and Drug Administration on Tuesday approved a new drug for idiopathic pulmonary ...

Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...

The overall cough in idiopathic pulmonary fibrosis market is expected to rise due to increasing prevalent cases over the globe and thus the surge in treatment options. The expected launch of emerging ...

IPF is a rare, progressive and fatal lung disease with a median survival of 2-5 years. 1 Pirfenidone is one of only two drugs approved to treat IPF, and for those patients able to tolerate treatment, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Prior to this trial, CS014 had positive outcomes in an ...

Esbriet (pirfenidone, Roche Holding AG) and Ofev (nintedanib, Boehringer Ingelheim GmbH) were approved to treat idiopathic pulmonary fibrosis (IPF) by the FDA two years ago – serendipitously on the ...

IPF patient survey provides new insights into disease burden and patient experience one decade after the approval of the first antifibrotics for IPF Clinical abstract reviews the ability of Bayesian ...